Step 1 topics → Musculoskeletal, Skin, and Connective Tissue → Systemic Sclerosis (Scleroderma)

Systemic Sclerosis (Scleroderma)

USMLE Step 1 trap: Reverses the antibody associations for limited vs diffuse scleroderma. Anti-centromere antibody is associated with limited scleroderma (CREST), while anti-Scl-70 is associated with diffuse scleroderma and worse prognosis.

Systemic sclerosis (scleroderma) is an autoimmune connective tissue disease defined by fibrosis of the skin and internal organs, vasculopathy, and immune dysregulation. USMLE Step 1 tests you on all axes — antibody associations, organ complications, and management — often in the same vignette. Students routinely flip anti-centromere and anti-Scl-70, which cascades into misidentifying the subtype and predicting the wrong pulmonary complication. Get the antibodies anchored first, and the rest flows logically. Expect a middle-aged woman with tight skin, Raynaud's, and some combination of GI, pulmonary, or renal findings — your job is to identify the subtype, predict the complication, and choose the right intervention.

The exam hits scleroderma from multiple angles: pure recall (which antibody goes with which subtype), clinical application (a vignette with rising creatinine and hypertension requiring a specific drug), and passage interpretation (a research scenario about lung disease screening). The antibody associations are a favorite trap — students routinely flip anti-centromere and anti-Scl-70, which then cascades into misidentifying the subtype and the expected complications. Get the antibodies anchored first, and the rest of the concept flows logically.

What makes scleroderma uniquely tricky on USMLE Step 1 is that the two subtypes have inverted pulmonary complication profiles — and steroid use, which feels intuitive for autoimmune disease, is actually dangerous in renal crisis. These counterintuitive facts are exactly what the exam exploits. Students who memorize facts without understanding the underlying logic get burned here. This page will fix that.

From real student decks
89%have cards covering this topic
76%have mature cards
1median lapses in 14 days

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: Anti-Scl-70 (anti-topoisomerase I) is associated with limited scleroderma and anti-centromere with diffuse disease.
Right: Anti-centromere antibody is associated with limited scleroderma (CREST), while anti-Scl-70 is associated with diffuse scleroderma and worse prognosis.
The mnemonic that saves this: 'Limited = centromere' — both limited and centromere are 'smaller/more contained' concepts. Anti-centromere is tightly associated with limited scleroderma (CREST syndrome), which has restricted skin involvement (distal to elbows/face). Anti-Scl-70 (anti-topoisomerase I) goes with diffuse scleroderma, where fibrosis spreads proximal to the elbows and involves internal organs early — and carries a worse prognosis. Flipping these on the exam means you'll also mispredict which pulmonary complication to expect, so get this anchor locked in first.
Common mistake
Wrong: Steroids are the treatment for scleroderma renal crisis.
Right: ACE inhibitors are the life-saving treatment for scleroderma renal crisis; steroids can actually precipitate renal crisis.
Steroids feel instinctive for autoimmune emergencies, but scleroderma renal crisis is a vasculopathic process — the kidney arterioles undergo intimal proliferation and fibrosis, causing renin-angiotensin activation and hypertensive crisis. ACE inhibitors interrupt that cycle directly and are the only treatment shown to improve survival. Steroids not only fail to help but are an independent risk factor for triggering renal crisis in diffuse scleroderma patients — so prescribing them here causes active harm. If the Step 1 vignette shows scleroderma plus new hypertension plus rising creatinine, the answer is an ACE inhibitor.
Common mistake
Wrong: Pulmonary hypertension is the main pulmonary complication of diffuse scleroderma.
Right: Diffuse scleroderma is more associated with interstitial lung disease (fibrosis), while pulmonary arterial hypertension is more characteristic of limited scleroderma.
This is the most counterintuitive fact in scleroderma: the more severe systemic subtype (diffuse) causes ILD/fibrosis, while the milder subtype (limited/CREST) is paradoxically more associated with pulmonary arterial hypertension. The logic: in CREST, the predominant pathology is vasculopathy — the same process that causes Raynaud's attacks the pulmonary vasculature over time, leading to PAH. Diffuse disease, on the other hand, drives fibrotic remodeling throughout the lungs. Screen diffuse patients with PFTs (looking for restrictive pattern + low DLCO); screen limited patients for PAH with echocardiography.
Common mistake
Gap: Misses that esophageal dysmotility is a defining CREST feature causing significant GI morbidity
The 'E' in CREST stands for Esophageal dysmotility, which causes dysphagia and GERD due to smooth muscle fibrosis of the lower esophagus.
The 'E' in CREST is esophageal dysmotility, and it's clinically significant enough that it should never be forgotten. Smooth muscle fibrosis of the lower esophagus causes two problems: dysphagia (food sticking, especially solids) and severe GERD from a dysfunctional lower esophageal sphincter. The GERD is chronic enough that Barrett's esophagus is a real downstream risk. On the exam, a CREST patient with heartburn, regurgitation, or dysphagia is pointing you to this feature — and management targets the GI symptoms directly (PPIs for GERD, pro-motility agents for dysmotility).
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know which antibody (anti-centromere vs anti-Scl-70 vs anti-RNA-pol-III) corresponds to limited scleroderma, diffuse scleroderma, and worst prognosis — and why flipping them is the #1 trap on this topic.
  2. Identify all five components of the CREST acronym (Calcinosis, Raynaud's, Esophageal dysmotility, Sclerodactyly, Telangiectasia) and recognize that esophageal dysmotility causes dysphagia and GERD via smooth muscle fibrosis of the lower esophagus.
  3. Recognize scleroderma renal crisis — new-onset hypertensive urgency with rising creatinine in a diffuse scleroderma patient — and know that ACE inhibitors are the life-saving treatment (not steroids, which can precipitate the crisis).
  4. Assign the correct pulmonary complication to the correct subtype: interstitial lung disease (fibrosis) with diffuse scleroderma, and pulmonary arterial hypertension with limited/CREST scleroderma — and know how each is screened.
  5. Select organ-directed therapy across scleroderma manifestations: calcium channel blockers for Raynaud's, ACE inhibitors for renal crisis, mycophenolate or cyclophosphamide for ILD, and endothelin receptor antagonists or PDE-5 inhibitors for pulmonary arterial hypertension.

Can you avoid these mistakes?

A 45-year-old woman with tight skin limited to her hands and face, Raynaud's phenomenon, and telangiectasias is found to have a positive anti-centromere antibody. What pulmonary complication is she most at risk for, and what screening test would you order?
A patient with diffuse scleroderma presents with severe headache, blood pressure of 185/110, and creatinine that has risen from 0.9 to 2.4 mg/dL over two weeks. She was recently started on prednisone for joint symptoms. What is the diagnosis, what is the treatment, and what drug may have contributed to this crisis?
A friend argues: 'Anti-Scl-70 is the limited scleroderma antibody because Scl-70 sounds like it only affects a small part.' How do you correct this reasoning, and what is the correct antibody-to-subtype pairing?
Match each CREST letter to its clinical consequence: which letter is responsible for GERD and dysphagia, which causes painful digital ulcers in cold weather, and which letter's complication carries the most significant long-term pulmonary mortality risk?

Related topics

Bone Cells and Matrix Endochondral vs Membranous Ossification Fracture Healing Stages Compartment Syndrome

See how your Anki deck covers this topic.

Upload your deck for a free audit →